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In this review, we fi rst discuss the current status of the extent of LN dissection for advanced gastric cancer and offer an optimal management approach in view of the results of recent clinical trials.
In contrast with results in patients with advanced gastric cancer, patients with early gastric cancer (EGC) have an excellent survival rate (>90%) after radical surgery [6, 7] . Lymph node metastases from EGC are relatively infrequent, and metastases to group N2 are even rarer [8] . Therefore, it might be appropriate to perform less invasive surgery for EGC. In the latter part of this article, we review limited gastrectomy for EGC.
Surgical anatomy of the gastric lymphatics
Knowledge of LN node staging is mandatory for understanding the ongoing debate regarding LN dissection. The very complex LNs of the stomach have been arranged into a very useful classifi cation by the Japanese Gastric Cancer Association (JGCA) [9] . According to this classifi cation, 16 different LN compartments (stations) are identifi ed surrounding the stomach. These LN stations are classifi ed into three groups that correspond to the location of the primary tumor and refl ect the likelihood of harboring metastases. Most perigastric LNs (stations [1] [2] [3] [4] [5] [6] are defi ned as group N1, whereas the nodes along the left gastric (station 7), common hepatic
Introduction
Gastric cancer is a very common disease worldwide and is the second most frequent cause of cancer death, affecting about one million people per year [1] . Surgery is the most effective and successful method of treatment for gastric cancer, and there is no doubt that systematic lymph node (LN) dissection is the most effective procedure to treat LN metastases of gastric cancer. However, the optimal extent of surgical intervention remains unresolved. Japanese and other Asian surgeons routinely perform an extended (D2) dissection to remove the nodes along the main branches of the celiac axis [2, 3] , while many Western surgeons perform more limited (D1) dissection-which removes only the nodal groups (station 8), splenic (station 11), and proper hepatic (station 12) arteries and along the celiac axis (station 9) are defi ned as group N2. Minor modifi cations of this schedule occur depending on the location of the primary tumor ( Fig. 1 ). For example, the LNs at the splenic hilum (station 10) also belong to group N2 when the tumor is located in the proximal stomach. The paraaortic LNs (station 16) are defi ned as group N3.
D1 versus D2 or D3 trials
Five RCTs comparing D1 and D2/D3 dissection have been performed. There have been two large-scale RCTs [10, 11] , two small-scale RCTs [12, 13] , and 1 smallinstitution trial [14] . Three major RCTs and one ongoing RCT [15] are summarized in Table 1 .
Dutch Gastric Cancer Group trial
The Dutch Gastric Cancer Study Group, involving 80 Dutch hospitals, conducted a large-scale, RCT in the Netherlands between 1989 and 1993 [10] . In this trial, 996 patients were centrally randomized; 711 patients (380 in the D1 group and 331 in the D2 group) underwent the allocated treatment with curative intent, and 285 patients required palliative treatment. D2 patients had higher postoperative mortality (10% vs 4% for D1; P = 0.004); they also had signifi cantly more complications (43% vs 25% for D1; P < 0.001), which led to a signifi cantly prolonged hospital stay for patients with a D2 dissection. Overall 5-year survival rates were similar in the D1 and D2 groups (45% for D1 and 47% for D2). The hazard ratio (HR) comparing the risk of death within 5 years after D2 surgery with that within 5 years after D1 surgery was 1.00 (95% confi dence interval [95% CI], 0.82-1.22). At a median follow-up of 11 years, 68% of the patients were deceased, 35% without and 65% with recurrent disease. At 11 years, survival rates were 30% for D1 and 35% for D2 (P = 0.53), with a risk of relapse of 70% for D1 and 65% for D2 (P = 0.43) [16] . Interestingly, when hospital deaths were excluded, survival rates were 32% for D1 (n = 365) and 39% for D2 (n = 299, P = 0.10), and the relapse risk of these patients (n = 664) was in favor of the D2 dissection group (P = 0.07). Furthermore, in the subset analysis, Fig. 1 . Lymph node station numbers according to the Japanese classifi cation of gastric carcinoma 2nd English edition reproduced from [9] , with permission. LN, Lymph node when hospital deaths were excluded, there was a significant survival and relapse advantage for patients with International Union Against Cancer (UICC) pN2 disease who had a D2 dissection (P = 0.01). Other stages showed no signifi cant differences (N0 P = 0.42; N1 P = 0.31; N3 P = 0.24).
This trial showed an extremely high hospital mortality after D2 dissection [17] . Such a high mortality was caused by a very low hospital volume. Lack of experience in dealing with major surgical complications after D2 dissection; namely, anastomotic leakage, pancreatic fi stula, and intraabdominal abscess, led to the high mortality. Low-quality surgery with high mortality immediately after operation could explain why D2 dissection was not found to be benefi cial. Furthermore, in this study, there was a high rate of protocol violations in terms of lymph node dissection [18] . If lymph nodes were harvested from stations that were not supposed to be included according to the protocol, this was called contamination. If lymph nodes were not harvested from stations that should have been harvested, this was called noncompliance. Contamination occurred in 6% of the D1 dissection group, and noncompliance occurred in 51% of the D2 group. Contamination in the D1 dissection group and noncompliance in the D2 group could have led to the small difference between the trial arms.
Medical Research Council Gastric Cancer Surgical Group Trial
In 1986, the Medical Research Council of Great Britain initiated a nationwide, multi-institutional, RCT comparing D1 dissection with D2 dissection in that country [11] .
Central randomization followed a staging laparotomy. Of 737 patients with histologically proven gastric adenocarcinoma registered, 337 patients were ineligible by staging laparotomy because of advanced disease. Thus, 400 patients were randomized, with 200 patients receiving D1 dissection and 200 patients receiving D2 dissection. Postoperative mortality was signifi cantly higher in the D2 group (13%) than in the D1 group (6.5%; P = 0.04) [19] . Postoperative complications were also significantly higher in the D2 group (46%) than in the D1 group (28%; P < 0.001), with the most frequent complications being anastomotic leakage (26% for D2 vs 11% for D1; P < 0.015), cardiac complications (8% for D2 vs 2% for D1; no signifi cant difference [NS]), and respiratory complications (8% vs 5% for D1; NS). In this trial, many surgeons thought that D2 distal gastrectomy included splenectomy, and splenectomy was carried out in many distal gastrectomy cases. Pancreatico-splenectomy was carried out in 56% of patients allocated to the D2 group and 4% of the D1 group. This was based on a misunderstanding of the defi nition of D2 gastrectomy by the JGCA. In Japan, splenectomy is included in D2 dissection only when a total gastrectomy is carried out. Together with thorough lymph node dissection of the lesser curvature, splenectomy causes serious ischemia of the remnant stomach, necrosis of the remnant stomach, or anastomotic leakage. Hospital death in the D2 dissection group was 13%; such a high mortality is no longer accepted for any cancer surgery. In fact, there was no difference in 5-year survival between the two arms (33% vs 35% for D1; HR, 1.10; 95%CI, 0.87-1.39).
Taiwanese trial
This study was a single-institutional trial that was carried out between 1993 and 1999. This is the only trial that showed a statistically signifi cant survival benefi t of D3 over D1 gastrectomy [14, 20] . Of 221 patients, 110 patients were randomly assigned to D1 surgery and 111 patients were randomly assigned to D3 surgery between 1993 and 1999. Overall 5-year survival was signifi cantly higher in patients assigned to D3 surgery than in those assigned to D1 surgery (59.5% vs 53.6%; P = 0.041). The HR comparing the risk of death within 5 years after D3 with that within 5 years after D1 surgery was 0.49 (95% CI, 0.32-0.77). Overall, 215 patients who had R0 resection had recurrence at 5 years (50.6% for D1 surgery and 40.3% for D3 surgery; P = 0.197). Five-year diseasespecifi c survival was signifi cantly higher in patients assigned to D3 surgery than in those assigned to D1 surgery (64.9% vs 58.5%; P = 0.044; HR, 0.69).
Small-scale RCT in South Africa
Between 1982 and 1986, a small-scale RCT was performed in South Africa, involving 43 patients who were randomized to D1 or D2 resection [12] . Although there were no hospital deaths, D2 gastrectomy was associated with longer operating time, more blood loss, longer hospital stays, and a higher reoperation rate, but there was no detailed analysis of complications. There was no survival difference at a median follow-up of 3.1 years.
Small-scale RCT in Hong Kong
Between 1987 and 1991, another RCT was conducted in Hong Kong [13] . This study randomized 55 patients to either D1 or D3 gastrectomy; D3 patients had longer operative times, greater transfusion needs, longer hospital stays, and more subphrenic abscesses than D1 patients. There was no detailed statistical analysis of postoperative complications in the D1 group. One patient in the D3 group died from operative complications. Overall survival was better in the D1 group (P = 0.07).
It is obvious that the two large-scale RCTs in the Netherlands and the United Kingdom showed the same tendency. The Dutch and MRC studies had extremely high hospital mortality after D2 dissection, 10% and 13%, respectively. Such a high mortality negated the survival benefi ts of D2 dissection. The critics of these trials have suggested that there was inadequate pretrial training of the surgeons; in particular, their lack of experience in treating major surgical complications led to the high hospital mortality. Morbidity and mortality are signifi cantly related to hospital volume [21] . The learning curve for a D2 gastrectomy may be up to 25 cases [22, 23] . The number of patients per hospital per year was 1.0 in the Dutch trial and 1.5 in the MRC trial. After these two trials with miserable short-term results, the Italian Gastric Cancer Study Group (IGCSG) performed a phase II study between 1994 and 1996 to assess the safety of D2 gastrectomy [24] . In this study, postoperative complications were seen in 20.9% of patients, with only 3.1% mortality. This trial was carried out in only nine hospitals, and only 18 surgeons participated in the trial. They avoided splenectomy in distal gastrectomy and the routine use of distal pancreatectomy in total gastrectomy. They also performed a phase III trial comparing D1 gastrectomy to D2 gastrectomy [15] . In that phase III trial, postoperative morbidity was 16.3% in D2 gastrectomy and 10.5% in D1 gastrectomy, and postoperative mortality was 1.3% after D1 but 0% after D2 gastrectomy. There were no signifi cant differences in the postoperative morbidity and mortality between the two groups. Therefore, D2 gastrectomy was regarded as a safe treatment for gastric cancer in experienced centers. The lack of experience with the D2 gastrectomy and with postoperative care led to a poor outcome in patients with D2 gastrectomy in the Dutch and MRC trials. The results of the phase III study by the IGCSG are awaited.
D2 versus D3 trial
In Japan, D2 gastrectomy is regarded as a safe operation, and D2 gastrectomy is a common practice in ordinary general hospitals. Therefore, in Japan, conducting a D1 versus D2 trial was considered unethical. Japanese surgeons fi rst introduced the D2 gastrectomy in the 1960s [25] . Since the 1980s, gastrectomy with more radical extended lymphadenectomy (D3; superextended lymphadenectomy) has been practiced at many specialized centers in Japan [26] [27] [28] [29] . In advanced gastric cancer, the incidence of microscopic metastases in the paraaortic nodes was 6% to 33% [29] . The 5-year survival for these patients has reached 12% to 23% after gastrectomy with super-extended lymph node dissection. In Japan, between 1995 and 2001, the Japanese Clinical Oncology Group (JCOG) conducted a randomized trial comparing D2 gastrectomy alone with D2 plus paraaortic node dissection (PAND) [30] . A total of 523 patients with curable T2b, T3, or T4 gastric cancer were randomly assigned to D2 lymphadenectomy alone (263 patients) or to D2 plus PAND (260 patients). The overall operative morbidity rate was 24.5%. The morbidity for the D2+PAND group was higher than that for the D2 alone group (28.1% and 20.9%, respectively), but there was no signifi cant difference between the groups (P = 0.067) [31] . There were four hospital deaths (0.8%), 2 patients in each group (P = 0.99). The 5-year overall survival rates after D2 plus PAND were not signifi cantly better than those after D2 alone (D2, 69.2% and D2+PAND, 70.3%; HR, 1.03; 95% CI, 0.77-1.37). The two survival curves were almost overlapping, while D2 plus PAND showed longer operation time and more blood loss than D2. This study concluded that prophylactic D2+PAND should not be carried out for curable gastric cancer.
Another phase III trial compared D2 to D2 plus PAND in Poland [32] . Of 275 patients enrolled, 141 patients were allocated to D2 alone and 134 patients were allocated to D2+PAND. The morbidity rates were 27.7% for D2 and 21.6% for D2 plus PAND (P = 0.248). The postoperative mortality rates were 4.9% for D2 and 2.2% for D2 plus PAND (P = 0.375). In this study, PAND did not result in increased morbidity and mortality, but the survival benefi ts remain to be analyzed.
In East Asia, another RCT comparing D2 with D2 plus PAND was carried out between 1995 and 2002 [33, 34] . A total of 269 patients were randomized, with 135 patients receiving D2 dissection and 134 patients receiving D2 plus PAND dissection. Postoperative morbidity was signifi cantly higher in the D2 plus PAND group (39%) than in the D2 group (26%; P = 0.023). Hospital mortality was 0.7% in the D2 group and 3.7% in the D2 plus PAND group (P = 0.12). The overall 5-year survival was 52.6% for the D2 group and 55.4% for the D2 plus PAND group; there was no survival benefi t of PAND over standard D2 lymphadenectomy (P = 0.801).
These three trials demonstrated that both D2 and D3 gastrectomy are safe treatments. However, at the present time, D3 dissection should not be performed for curable gastric cancer, because evidence of survival benefi ts is lacking (Table 2) .
Should splenectomy or pancreatico-splenectomy be carried out routinely in the treatment of cancer of the upper third of the stomach?
Pancreatico-splenectomy should not be carried out routinely
No RCT has proven the survival benefi ts of pancreatico-splenectomy (PS) with total gastrectomy. In Japan, PS for lymph node dissection around the splenic artery and splenic hilum had been widely performed [35, 36] , because this has been proposed as a radical procedure for complete removal of metastatic lymph nodes along the splenic artery. However, a Japanese retrospective analysis showed no survival benefi t from these procedures [37, 38] , and PS was proven to be dangerous in RCTs [16, 18] . In the MRC trial, PS was performed in 56% of patients allocated to the D2 gastrectomy group, and PS had a marked adverse effect on both morbidity (58% for D2+PS and 30% for D2 without PS; P < 0.001) and mortality (16% for D2+PS and 9% for D2 without PS; P = 0.01). In the Dutch trial, PS was performed for 108 patients in the D1 and D2 groups, and the morbidity and mortality rates were 40% and 12%, respectively (relative risk, 3.43; 95% CI, 2.49-4.72) [15] . In the JCOG 9501 trial, PS was identifi ed as a signifi cant independent risk factor for complications [31] . PS was performed in only 22 of the 523 registered patients, and complications were identifi ed in 13 patients (59%). There is no doubt that PS results in a high incidence of complications. In the Dutch trial, in a subgroup analysis of patients who did not have a PS (n = 603), morbidity and mortality were signifi cantly higher in the D2 group, but the 11-year survival rate was signifi cantly better in the D2 group than in the D1 group (31% vs 42%; P = 0.02) [39] . There appears to be a survival benefi t of D2 gastrectomy if procedures that increase morbidity and mortality, such as PS, can be avoided.
Therefore, PS is considered to be benefi cial only when there is direct tumor invasion to the pancreas.
Is splenectomy indeed effective treatment?
In the JCOG 9501 trial and the IGCSG phase III trial, a low incidence of hospital deaths was achieved because a pancreas-preserving splenectomy was generally used [15, 31] . Pancreas-preserving splenectomy is considered to be a safe procedure that does not decrease surgical [33, 34] (P = 0.023) (P = 0.107) (P = 0.801) JCOG, Japan Clinical Oncology Group; PAND, paraaortic node dissection; HR, hazard ratio; 95% CI, 95% confi dence interval curability [40] [41] [42] . However, it is not known whether splenectomy contributes to survival. From the Japanese experience with splenectomy, the incidence of hilar nodal metastasis ranged from 0-2% for distal and middle-third gastric cancer, to 15% for proximal-third tumors, and 21% for tumors that infi ltrate the entire stomach. Based on retrospective data, hilar nodal metastasis was not found in EGC [43] [44] [45] [46] . These data suggested that splenectomy was crucial for the curative resection of proximal advanced gastric cancer and might improve the prognosis.
Two RCTs compared the effectiveness and safety of gastrectomy with splenectomy to gastrectomy alone in patients with gastric cancer (Table 3) . One of these RCTs was carried out in Chile [47] , and the other was carried out in Korea [48] . Both studies were performed in single institutions. In Chile, between 1985 and 1992, 187 patients with gastric cancer, including early-stage cases, were randomized. However, this study did not state how the patients were randomized. Total gastrectomy was performed for all patients. The frequency of septic complications, including postoperative fever higher than 38°C, pulmonary complications, and subphrenic abscess, was signifi cantly higher in the splenectomy group than in the gastrectomy-alone group (fever, 50% vs 39%; P < 0.04; pulmonary, 39% vs 24%, P < 0.008; subphrenic abscess, 11% vs 4%, P < 0.05, respectively). There was no signifi cant difference between the groups in the hospital mortality rate (4.4% for splenectomy vs 3.1% for gastrectomy alone; P > 0.7). In this study, the survival statistics excluded the operative mortality rate. The 5-year survival rates were 42% for splenectomy and 36% for gastrectomy alone; there was no signifi cant difference between the groups (P > 0.5). In subgroup analysis, there was no survival benefi t for stage II, IIIA, and IIIB cancer.
In the other trial, carried out in Korea between 1995 and 1999, 207 patients with gastric cancer were randomized to either total gastrectomy or total gastrectomy plus splenectomy for lymph node dissection at the splenic hilum and along the splenic artery. Overall, 103 patients had the spleen-preserving procedure, and 104 had splenectomy. Postoperative morbidity was 8.7% in the spleen-preserving group and 15.4% in the splenectomy group, but there was no signifi cant difference between the groups (P = 0.142). One patient (1.0%) in the spleen-preserving group and 2 patients (1.9%) in the splenectomy group died from postoperative complications, but this difference was not signifi cant (P = 1.000). The incidence of metastasis at the splenic hilum and along the splenic artery was 10.6% and 17.3%, respectively. The 5-year survival rate was 48.8% for patients in the spleen-preserving group and 54.8% in the splenectomy group; there was no signifi cant difference (P = 0.503). The 5-year survival rate of patients with lymph node metastasis at the splenic hilum was 0%, with or without splenectomy. In the subgroup with lymph node metastasis along the splenic artery, the 5-year survival rate was 20.0% in the spleen-preserving group and 23.4% in the splenectomy group (P = 0.753). Therefore, these results did not support the use of prophylactic splenectomy to remove macroscopically negative lymph nodes near the spleen in patients undergoing total gastrectomy for proximal gastric cancer.
In Japan, an RCT to evaluate splenectomy for upperthird advanced gastric cancer is ongoing [49] . This trial includes the evaluation of long-term survival, postoperative morbidity, mortality, and quality of life. Registration of about 500 patients has been completed, and the results of this study are awaited.
Mediastinal lymph node dissection for gastric cancer with esophageal invasion
Siewert and Stein [50] developed a now widely used classifi cation of carcinomas involving the stomach and esophagus into three types: adenocarcinoma of the distal esophagus, which may infi ltrate the esophagogastric junction from above (type I); true cardia carcinoma arising from the esophagogastric junction (type II); and subcardial gastric carcinoma that infi ltrates the esopha- [52, 53] . In this trial, 220 patients with Siewert type I and type II tumors were enrolled; 106 patients were assigned to THE, and 114 were assigned to TTE. THE was associated with fewer pulmonary complications, a shorter duration of mechanical ventilation, and shorter stays in the intensive care unit (ICU) and in the hospital. Two patients in the THE group and 5 patients in the TTE group died in hospital; there difference in hospital mortality between the two groups was not signifi cant (P = 0.45). The 5-year survival rate was 34% for the THE group and 36% for the TTE group (P = 0.71). According to the Siewert classifi cation, 90 patients (43 patients in THE group and 47 patients in the TTE group) were classifi ed as having type I tumors, and 115 patients (52 patients in the THE group and 63 patients in the TTE group) were classifi ed as having type II tumors. The difference in overall 5-year survival was as large as 14% (37% for THE vs 51% for TTE; P = 0.33) for type I tumors, while it was negligible for type II tumors (31% for THE and 27% for TTE; 5-year survival difference,-4%; P = 0.81). The results of this study strongly suggested that thorough mediastinal dissection via right thoracotomy is needed for type I tumors but not for type II tumors, although there was no signifi cant difference in survival.
In view of the results of these two trials, the transhiatal approach is regarded as the standard treatment for patients with Siewert type II and III tumors. 
The treatment of early gastric cancer
There is a major difference in the proportion of EGCs in Japan and Korea compared to the rest of the world. EGCs now account for nearly 50% of all gastric cancers treated at major institutions in Japan and Korea [54, 55] . However, in Western countries, the frequency of EGC was only 10%-20% [56, 57] . Therefore, the majority of reports on EGC have been published from Japan. However, there are a few reports of RCTs dealing with the extent of lymphadenectomy for EGC. The JGCA issued a set of treatment guidelines to help standardize treatment (Table 5 ) [2] . In Japan, resection of at least two-thirds of the stomach with D2 lymphadenectomy has been conventional surgical treatment for gastric cancer, including EGC, though conservative treatments such as endoscopic mucosal resection or function-preserving limited gastrectomy for EGC have recently been performed [58, 59] .
The indications for endoscopic resection
Endoscopic resection is comparable in many respects to surgical therapy, with the advantages of being less invasive and more economical. The extremely low incidence of lymph node involvement in certain stages of EGC means that cure can be accomplished by such local treatment. Therefore, endoscopic resection is indicated for EGCs without lymph node metastasis. According to the guidelines, the accepted indications for endoscopic resection are: (1) well-differentiated elevated cancers less than 2 cm in diameter; and (2) small (≤1 cm) depressed lesions without ulceration. In addition, these lesions must be moderately or well-differentiated cancers confi ned to the mucosa and have no lymphatic or vascular involvement. These criteria for node-negative gastric cancer were defi ned using a large retrospective database of more than 5000 EGC patients who underwent gastrectomy with D2 lymphadenectomy [60] . The guidelines show the extended indications for which endoscopic resection may be appropriate, and these indications include: differentiated-type mucosal cancer without ulceration greater than 2 cm in diameter; differentiated-type mucosal cancer with ulceration up to 3 cm in diameter; undifferentiated-type mucosal cancer without ulceration up to 2 cm in diameter; and, in the absence of lymphovascular invasion, a tumor not deeper than submucosal level 1 (less than 500 μm; Fig.  2 ). However, extending the indications for endoscopic resection remains controversial, because of the lack of supportive clinical evidence. In Japan, a phase II trial of endoscopic resection for EGC, which is clinically diagnosed as belonging to the expanded indications, is ongoing [61] .
Surgical treatment for EGC
According to the Japanese guidelines, modifi ed gastrectomy (MG) should be performed for EGC (Table 6) . MG is classifi ed as MG A and MG B according to the extent of resection and lymph node dissection [2] . MG A involves the dissection of group N1 nodes, those in the left gastric artery (station 7), and those in the anterior wall of the common hepatic artery (station 8a). MG B involves dissection of the lymph nodes in the celiac axis (station 9), in addition to MG A. MG A is indicated for clinically observed mucosal cancers or differentiated-type submucosal cancers smaller than 1.5 cm in diameter, and MG B is indicated for submucosal cancers and EGCs smaller than 2 cm with clinical N1 disease. In cases of EGC in which endoscopic resection is not appropriate, though there is a low risk of lymph node metastasis, MG A is performed. Basically, MG A is indicated for apparent intramucosal cancers with no lymph node involvement in which endoscopic resection is not appropriate, or for differentiated submucosal cancers of about 1.5 cm diameter that are found to be node-negative during operation. MG B can be used for cases of apparent submucosal cancers that are diagnosed during the operation as being node-negative and it can be used for patients with tumors of less than 2 cm who are suspected of having metastasis to the group N1 lymph nodes for which dissection would result in cure. These criteria were established on the basis of retrospective data [8, [62] [63] [64] [65] [66] [67] [68] . However, pre-or intraoperative diagnosis is not always accurate, so it is inevitable that over-diagnosis occurs when surgeons decide whether limited resection is feasible.
Limited resection of the stomach for early gastric cancer
Recently, pylorus-preserving gastrectomy (PPG) or proximal gastrectomy has been performed for EGC when the tumor location is suitable for these limited resections. The purpose of these approaches is to preserve the gastric reservoir, and they have a favorable outcome. However, the extent of lymph node dissection in these approaches is also limited. Therefore, the surgeon must carefully judge whether these limited gastrectomies are appropriate.
Pylorus-preserving gastrectomy
PPG is currently indicated for EGC in the gastric body [69, 70] . PPG is a modifi cation of distal gastrectomy, preserving 2-3 cm of the pyloric cuff, which maintains pyloric ring function. In a retrospective study, the incidences of dumping syndrome, biliary refl ux, and gallbladder stone formation were lower, and body weight recovery was better following PPG than after Billroth I reconstruction [71] [72] [73] [74] [75] . In a prospective randomized trial, only dumping syndrome was reduced [76] . The indication for PPG is early cancer located in the middle third of the stomach without lymph node metastasis, excluding patients who are candidates for endoscopic resection. In PPG, all regional lymph nodes, except for the suprapyloric nodes, should be dissected, as in the standard D2 gastrectomy. It is unnecessary to dissect suprapyloric nodes (station 5) routinely, because metastases to suprapyloric nodes are extremely uncommon from cancer in the middle third of the stomach [69, 77, 78] .
For preserving pyloric function, it is necessary that 2-3 cm of the pyloric cuff is preserved, so PPG is indicated for tumors more than 4 cm from the pyloric ring to maintain the distal margin.
Proximal gastrectomy
Proximal gastrectomy is currently indicated for EGC only when at least half of the stomach can be preserved to maintain both the curability of the operation and the functional capacity of the remnant stomach [79] . Splenectomy is not performed. Therefore, nodes of the Fig. 2 . Japanese guideline criteria for endoscopic resection. Size is shown in mm. Black area, Guideline criteria for endoscopic resection; gray area, criteria for extended endoscopic resection; white area, no indication for endoscopic resection. UL, With ulcerated lesion; SM1, submucosal level 1 (≤500 μm from lamina muscularis mucosae); SM2, submucosal level 2 (>500 μm from lamina muscularis mucosae) splenic hilum (station 10) and the distal splenic nodes (station 11d) are not dissected, and the dissection of the distal lesser curvature nodes (station 3) is complete because of the preservation of the distal stomach. There are retrospective data that support this procedure for EGC in the upper third of the stomach. There were no positive nodes along the right gastroepiploic vessels (station 4d), suprapyloric nodes (station 5), infrapyloric nodes (station 6), nodes in the splenic hilum (station 10), or nodes along the distal splenic artery (station 11d) in 258 EGCs of the upper third of the stomach in which total gastrectomy + D2 lymphadenectomy was performed [79] . Prospective studies have demonstrated that proximal gastrectomy for early upper-third gastric cancer can be performed safely with an excellent cure rate [80] [81] [82] . Some studies have shown improvement of postoperative absorption and body weight recovery to be better after proximal than after total gastrectomy [83, 84] .
Future perspectives
There is no doubt that gastrectomy with regional lymph node dissection is the only treatment modality for advanced gastric cancer. In Japan and Korea, gastrectomy with D2 lymphadenectomy is the gold standard of treatment for advanced gastric cancer. However, several studies have revealed that more extended resection than D2 surgery has no impact on survival. In order to improve locoregional control of gastric cancer, multimodal treatment involving chemotherapy or radiotherapy in addition to surgery is thought to be a promising treatment strategy. Survival benefi ts from adjuvant chemotherapy or chemoradiotherapy have been demonstrated in some studies [85] [86] [87] . Moreover, molecular targeting agents, such as bevacizumab, cetuximab, and panitumumab, have been introduced to clinical practice for the treatment of gastric cancer [88, 89] . To improve the survival of patients with advanced gastric cancer it is necessary to use these active new agents effectively in addition to conventional cytotoxic agents before or after surgery. On the other hand, for EGC, it is important to clarify the indications for limited resection, including endoscopic resection. The extent of the indications for endoscopic resection should be made clear, and for patients with EGC in whom endoscopic resection is not indicated, sentinel node navigation surgery might be considered. Sentinel node navigation surgery might be able to identify clinically undetectable lymph node metastases and provide essential information for performing individualized selective lymphadenectomy [90] [91] [92] .
